-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Enzaplatovir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1323077-89-9.gif)
| Category | Respiratory syncytial Virus (RSV) |
| CAS | 1323077-89-9 |
| Description | Enzaplatovir (BTA-C585) is an orally bioavailable fusion inhibitor for respiratory syncytial virus (RSV) infection. |
Product Information
| Synonyms | Enzaplatovir|1323077-89-9|UNII-OZ40XB915E|OZ40XB915E|(3R)-4-(3-methyl-1,2-oxazole-4-carbonyl)-3-(6-methylpyridin-3-yl)-1,4,7-triazatricyclo[7.3.0.03,7]dodeca-9,11-dien-8-one|(R)-1-(3-Methylisoxazole-4-carbonyl)-10a-(6-methylpyridin-3-yl)-2,3,10,10a-tetrahydroimidazo[1,2-a]pyrrolo[1,2-d]pyrazin-5(1H)-one|Enzaplatovir [INN]|SCHEMBL2337230|CHEMBL4581965|HY-109004|CS-0030435|Q27285922|(10aR)-1-(3-Methyl-1,2-oxazole-4-carbonyl)- 10a-(6-methylpyridin-3-yl)-2,3,10,10a-tetrahydro- 1H,5H-imidazo(1,2-a)pyrrolo(1,2-d)pyrazin-5-one|1H,5H-Imidazo(1,2-a)pyrrolo(1,2-d)pyrazin-5-one, 2,3,10,10a-tetrahydro-1-((3-methyl-4-isoxazolyl)carbonyl)-10a-(6-methyl-3-pyridinyl)-, (10aR)- |
| Molecular Weight | 377.40 |
| Molecular Formula | C20H19N5O3 |
| Canonical SMILES | CC1=NC=C(C=C1)C23CN4C=CC=C4C(=O)N2CCN3C(=O)C5=CON=C5C |
| Boiling Point | 663.0±55.0 °C at 760 mmHg |
| Flash Point | 354.8±31.5 °C |
| Purity | ≥99% |
| Density | 1.5±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 200 mg/mL(529.94 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 6 mg/mL (15.90 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 5 mg/mL (13.25 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 5 mg/mL (13.25 mM); Clear solution |
| Appearance | White to light yellow (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 660 |
| Exact Mass | 377.14878949 |
| Index Of Refraction | 1.731 |
| In Vitro | Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor. |
| Target | RSV |
| Vapor Pressure | 0.0±2.0 mmHg at 25°C |
| XLogP3-AA | 0.7 |
